Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biovail Corporation
Biovail Announces Termination of HSR Waiting Period, Closing of Acquisition of U.S. Rights to Wellbutrin XL®
June 6th, 2009
Biovail Corporation (NYSE, TSX: BVF) announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act has expired with respect to the acquisition of U.S. rights to Wellbutrin XL® (bupropion hydrochloride extended-release tablets) by its subsidiary, Biovail Laboratories International SRL, from GlaxoSmithKline plc (GSK). Under the terms of the agreement, which closed today, Biovail has paid $510 million to GSK to acquire the full U.S. rights to Wellbutrin XL®. Wellbutrin XL® is indicated for the treatment of major depressive disorder and seasonal affective disorder. About Biovail Corporation Biovail Corporation is a...
Source: Law & Health Weekly (2009-06-06)
|
